HK Stock Market Move | PEGBIO CO-B (02565) rose as much as over 30%, with expectations rising for pegvisomant's medical insurance inclusion and the innovative drug pipeline continuing to advance.

PEGBIO CO-B (02565) rose as much as over 30% this morning to HK$5, with current turnover of approximately HK$80.5163 million. On the news front, the company's core product, beinaglutide injection (Paidakang), has received marketing approval from the National Medical Products Administration. As a once-weekly GLP-1 receptor agonist, the product features differentiation such as treating from initiation without the need for dose titration. The company previously entered into an exclusive commercialization partnership with Tengrui Pharmaceutical for the Chinese mainland, continuously advancing the product's commercialization layout across medical institutions and online channels. Notably, beinaglutide has entered the relevant procedures for adjustment of the 2026 National Medical Insurance Catalog. As the announcement of the new round of the National Medical Insurance Catalog approaches, the product's medical insurance access progress has drawn market attention. If successfully included in medical insurance, it is expected to further enhance patient accessibility to medication and create conditions for subsequent commercialization ramp-up. In addition, the company continues to advance R&D of next-generation innovative drugs for metabolic diseases. Among them, the circular RNA project CR059 is dedicated to achieving long-acting GLP-1 expression, with preliminary studies showing potential for extending dosing intervals; the APGP6 project focuses on the differentiated therapeutic direction of fat reduction while preserving lean body mass during weight loss, providing new R&D reserves for the company's long-term layout in the metabolic disease field.